Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a common gout pill ease the aftermath of a blood clot?

NCT ID NCT06440694

Disease control Sponsor: Ottawa Hospital Research Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jul 24, 2026 · Updated 3 times

Summary

This pilot study is testing whether a low dose of colchicine, a drug usually used for gout, can reduce the risk of post-thrombotic syndrome (PTS) after a deep vein thrombosis (DVT) in the leg. PTS can cause chronic pain, swelling, and skin changes. The trial will enroll 150 adults with a first DVT, giving them either colchicine or a placebo daily for 180 days. The main goal is to see if a larger study is feasible, not yet to prove the drug works.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Colchicine (0.5 mg daily for 180 days)
What this could lead to
If it works, this could point toward a simple, affordable way to prevent long-term leg pain and swelling after a blood clot.
What could go wrong
This is a small pilot trial focused on feasibility, not yet on proving effectiveness. Colchicine can cause diarrhea and other side effects, and it may not reduce post-thrombotic syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Consenting patients 18 years of age or older with a first, acute, symptomatic proximal (popliteal vein or more proximal) objectively confirmed DVT of the lower extremity will be eligible to participate in the study. Exclusion Criteria: 1. History of an allergic reaction or significant sensitivity to colchicine. 2. Requirement of colchicine for other indications. 3. Active or chronic diarrhea, or documented inflammatory bowel disease (i.e., Crohn's disease or ulcerative colitis), collagenous colitis or irritable bowel syndrome or existing blood dyscrasias. 4. Known or suspected, recent (\<30 days) or active infections (acute or chronic). 5. History of cirrhosis, chronic active hepatitis, or severe liver disease. 6. Recent (\<30 days) or chronic use of systemic (oral, intravenous) immunosuppressive drugs (including but not limited to steroids, tumor necrosis factor-alpha blockers, cyclosporine). 7. Known active cancer. 8. Any of the following as measured within the past 1-3 months or at screening: alanine, or aspartate aminotransferase \>3 times the upper limit of normal, total bilirubin \>2 times the upper limit of normal and a creatinine clearance by Cockcroft-Gault formula \<30 mL/min. 9. Pregnancy, breast feeding or may be considering pregnancy during the study period or women of childbearing potential unwilling to use appropriate contraception during sex; 10. The use of medication with known drug-to-drug interactions (including but not limited to erythromycin or clarithromycin). 11. Unable or unwilling to provide consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Venous thromboembolism are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Inflammation Postthrombotic Syndrome venous thromboembolism post-thrombotic syndrome prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Venous thromboembolism

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre de recherche du Centre hospitalier de l'Université de Montréal

    RECRUITING

    Montreal, Quebec, H2X 0A9, Canada

  • The Ottawa Hospital General Campus

    RECRUITING

    Ottawa, Ontario, K1H 8L6, Canada

  • The Sir Mortimer B. Davis Jewish General Hospital

    NOT_YET_RECRUITING

    Montreal, Quebec, H3T 1E2, Canada

  • Windsor Regional Hospital

    RECRUITING

    Windsor, Ontario, N8W2X3, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.